PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) The optimal duration of immune checkpoint blockade (ICB) in lung cancer remains undefined. Indefinite treatment in long-term responders increases healthcare burden, exposes patients to avoidable toxicities, and is not supported by any clinical and biological rationale or translational data. Prospective strategies to determine the optimal duration of immunotherapy in lung cancer are urgently needed. Annals of Oncology December 30, 2025 Original source
Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment <p>Prostate Cancer and Prostatic Diseases, Published online: 26 December 2025; <a href="https://www.nature.com/articles/s41391-025-01069-1">doi:10.1038/s41391-025-01069-1</a></p>Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment Prostate Cancer Journal December 26, 2025 Original source
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study <p>Prostate Cancer and Prostatic Diseases, Published online: 26 December 2025; <a href="https://www.nature.com/articles/s41391-025-01068-2">doi:10.1038/s41391-025-01068-2</a></p>Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study Prostate Cancer Journal December 26, 2025 Original source
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer <p>Prostate Cancer and Prostatic Diseases, Published online: 24 December 2025; <a href="https://www.nature.com/articles/s41391-025-01066-4">doi:10.1038/s41391-025-01066-4</a></p>Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer Prostate Cancer Journal December 24, 2025 Original source
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study The TROPION-Breast01 study (NCT05104866) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy (ICC) in patients with previously treated, inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2‒) breast cancer. Here we report results from the final… Annals of Oncology December 23, 2025 Original source
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies <p>Prostate Cancer and Prostatic Diseases, Published online: 23 December 2025; <a href="https://www.nature.com/articles/s41391-025-01071-7">doi:10.1038/s41391-025-01071-7</a></p>Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies Prostate Cancer Journal December 23, 2025 Original source
Prognostic Value of Body Fat Density in Colorectal Cancer Adjuvant Treatment: A Retrospective Cohort Study . <br /> Nutrition and Cancer Journal December 23, 2025 Original source
[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula A 30-year-old woman presented to the Vascular Anomalies Centre at Shanghai Ninth People's Hospital in February, 2021, for a worsening and painful left inguinal arteriovenous fistula, which had been diagnosis 7 years previously following a strain 10 years ago. Initial endovascular embolisation in 2014 provided only transient relief, with subsequent symptom recurrence, progressive deep vein thrombosis, limb oedema, and claudication.… The Lancet Oncology December 23, 2025 Original source
[Review] Development of a core outcome set for adolescents and young adults with cancer Adolescents and young adults aged 15–39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards.… The Lancet Oncology December 23, 2025 Original source
[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus,… The Lancet Oncology December 23, 2025 Original source
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment Historically, the assessment of surgical outcomes in patients with glioma has been focused on technical outcomes, such as volumetric analysis of the residual tumour, progression-free survival, and overall survival. Other outcomes, such as neurological deficits, can be challenging to assess in an objective, quantifiable, and comprehensive manner. As a result, no consensus is available on methods to systematically evaluate perioperative… The Lancet Oncology December 23, 2025 Original source
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional… The Lancet Oncology December 23, 2025 Original source
[Articles] Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial Centralised EHR-facilitated, symptom surveillance and collaborative care management are more beneficial than symptom surveillance alone in reducing the population burden of SPPADE symptoms in oncology patients. The Lancet Oncology December 23, 2025 Original source
[Articles] Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes. The Lancet Oncology December 23, 2025 Original source
[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial Independent review facility-assessed progression-free survival and overall survival were significantly better in the tiragolumab plus atezolizumab and chemotherapy group compared with chemotherapy alone for unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma. These data support the rationale for exploring dual checkpoint inhibition added to chemotherapy for this group of patients with a high unmet need. The Lancet Oncology December 23, 2025 Original source
[Articles] First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial These results support the additional benefit of tiragolumab combined with atezolizumab and chemotherapy for patients with treatment-naive, locally advanced unresectable or metastatic oesophageal cancer. Further validation of tiragolumab plus atezolizumab and chemotherapy has been performed in the phase 3 SKYSCRAPER-08 trial (NCT04540211). The Lancet Oncology December 23, 2025 Original source
[Articles] Cancer mortality rates by detailed occupation among US working-age adults between 2020 and 2023: a population-based study US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation. The Lancet Oncology December 23, 2025 Original source
[Articles] Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC. The Lancet Oncology December 23, 2025 Original source
[Articles] Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study Overall, these results do not support ALND for all patients with ypN1mi on sentinel lymph node biopsy treated with nodal radiotherapy; however, tumour biology should be taken into account when considering ALND omission. The Lancet Oncology December 23, 2025 Original source
[Articles] Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma. The Lancet Oncology December 23, 2025 Original source